KALVISTA PHARMACEUTICALS, INC.
One Kendall Square,
Bld 200, Ste 2203
Cambridge, MA 02139
December 29, 2016
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Jeffrey Gabor Division of Corporation Finance |
|||||
| Re: | KalVista Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed December 20, 2016 File No. 333-215185 |
|||||
Via EDGAR—Acceleration Request
| Requested Date: | January 3, 2017 | |||||
| Requested Time: | 4:00 p.m. Eastern Time | |||||
Ladies and Gentlemen:
KalVista Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Effie Toshav, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| KALVISTA PHARMACEUTICALS, INC. | ||
| By: | /s/ Benjamin L. Palleiko | |
| Benjamin L. Palleiko Chief Financial Officer | ||
| cc: |
Thomas Andrew Crockett, Chief Executive Officer KalVista Pharmaceuticals, Inc.
Robert A. Freedman, Esq. Effie Toshav, Esq. Fenwick & West LLP |